ClinicalTrials.gg
RecruitingNCT07283809EuroHeart ITAUpdated Jan 12, 2026

European Unified Registries for Heart Care Evaluation and Randomised Trials Italy

An observational study in ACS - Acute Coronary Syndrome, sponsored by Heart Care Foundation. Recruiting at 57 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Heart Care Foundation · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.

Planned enrollment
8th of 52
5,000 · median 1,000
Started
2024
with 7 others
Observational
53 of 138
13 open now
Primary completion
2027-09
later than 20 of 28 live
Registered
131st of 138
by date
Lead sponsor
6 of 138
Heart Care Foundation

Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 8th largest by planned enrollment of the 52 observational ones that give a count, is one of 8 that started in 2024, is one of 53 observational ones, reaches primary completion later than 20 of the 28 other live ones, and was the 131st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Acute Coronary Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and/or harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.

03

Conditions studied

  • ACS - Acute Coronary Syndrome

Keywords

  • Quality indicators
  • ACS
  • STEMI
  • NSTEMI
  • ESC
  • Guidelines
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with ACS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years of age.
  • Males and females at birth.
  • At least one of the following clinical conditions:
  • Hospitalization for Acute Coronary Syndrome (ACS)
  • Heart failure (HF, outpatients, and/or inpatients)
  • Atrial fibrillation (A Fib, outpatients and/or inpatients)
  • Signed for the study and for privacy.

Exclusion criteria

Exclusion Criteria:

  • patients who do not sign the consent to participate in the project and/or Privacy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherAdherence to European Society of Cardiology (ESC) quality indicators

    EuroHeart is an initiative of the European Society of Cardiology (ESC) supporting continuous quality-of-care improvement through individual patient data collection. The present registry component refers specifically to the Italian implementation of the EuroHeart programme, aimed at monitoring and improving adherence to ESC quality indicators within Italian clinical practice.

06

What researchers measure

Primary outcomes

  1. Adherence to ESC Quality indicators (STEMI patients reperfused)

    Proportion of patients with STEMI reperfused among those eligible (onset of symptoms to diagnosis \<12 hours)

    Time frame: From enrollment to 12 months follow-up

  2. Adherence to ESC Quality indicators (STEMI patients reperfused <90 min)

    Proportion of patients with STEMI who receive timely reperfusion with PCI (wire crossing) within 90 minutes from initial diagnostic ECG

    Time frame: From enrollment to 12 months follow-up

  3. Adherence to ESC Quality indicators (coronary angiography in NSTEMI patients within 24 hours)

    Rate of NSTEMI patients who receive invasive within 24 hours from their diagnosis

    Time frame: From enrollment to 12 months follow-up

  4. Adherence to ESC Quality indicators (radial access)

    Use of radial access in case of invasive strategy for patients with STEMI and NSTEMI

    Time frame: From enrollment to 12 months follow-up

  5. Adherence to ESC Quality indicators (time to reperfusion in STEMI patients)

    The time between the initial STEMI diagnosis and arterial access (absolute value) for primary PCI

    Time frame: From enrollment to 12 months follow-up

  6. Adherence to ESC Quality indicators (pre-discharge LVEF evaluation in STEMI and NSTEMI patients)

    The proportion of patients with STEMI and NSTEMI who have an assessment of their left ventricular ejection fraction (LVEF) before hospital discharge

    Time frame: From enrollment to 12 months follow-up

  7. Adherence to ESC Quality indicators (in hospital LDL-c evaluation in STEMI and NSTEMI patients)

    The proportion of patients with STEMI and NSTEMI who have their LDL cholesterol measured during hospitalization

    Time frame: From enrollment to 12 months follow-up

  8. Adherence to ESC Quality indicators (DAPT prescription at discharge in STEMI and NSTEMI patients)

    Proportion of patients with STEMI and NSTEMI discharged on dual antiplatelet therapy

    Time frame: From enrollment to 12 months follow-up

  9. Adherence to ESC Quality indicators (LLA prescription at discharge in STEMI and NSTEMI patients)

    Proportion of patients discharged from hospital on Lipid Lowering Agents (LLA)

    Time frame: From enrollment to 12 months follow-up

  10. Adherence to ESC Quality indicators (ACEi/ARB/ARNI prescription at discharge in patients with LVEF ≤40%)

    Proportion of patients with LVEF ≤40% who are discharged from hospital on angiotensin converting enzymes inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI)

    Time frame: From enrollment to 12 months follow-up

  11. Adherence to ESC Quality indicators (Beta blockers prescription at discharge in patients with LVEF ≤40%)

    Proportion of patients with LVEF ≤40% who are discharged from hospital on beta blockers.

    Time frame: From enrollment to 12 months follow-up

Secondary outcomes

  1. Cardiovascular and non-cardiovascular events during follow-up

    Proportion of patients with clinical events at 12 months

    Time frame: 12 months follow-up

07

Study locations

38 of 57 sites recruiting
08

References and documents

Publications

  • Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H; ESC Scientific Document Group; Halvorsen S, Jernberg T, Jortveit J, Blondal M, Ibanez B, Hassager C. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care. 2021 Apr 8;10(2):224-233. doi: 10.1093/ehjacc/zuaa037. PubMed 33550362 ↗
  • Batra G, Aktaa S, Camm AJ, Costa F, Di Biase L, Duncker D, Fauchier L, Fragakis N, Frost L, Hijazi Z, Juhlin T, Merino JL, Mont L, Nielsen JC, Oldgren J, Polewczyk A, Potpara T, Sacher F, Sommer P, Tilz R, Maggioni AP, Wallentin L, Casadei B, Gale CP. Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):609-620. doi: 10.1093/ehjqcco/qcac068. PubMed 36243903 ↗
  • Aktaa S, Batra G, Cleland JGF, Coats A, Lund LH, McDonagh T, Rosano G, Seferovic P, Vasko P, Wallentin L, Maggioni AP, Casadei B, Gale CP; Heart Failure Association of the European Society of Cardiology. Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). Eur Heart J. 2022 Jun 14;43(23):2185-2195. doi: 10.1093/eurheartj/ehac151. PubMed 35443059 ↗
  • Association of Cardiovascular Nursing and Allied Professions (ACNAP); Association for Acute CardioVascular Care (ACVC); European Association of Percutaneous Cardiovascular Interventions (EAPCI); EURObservational Research Programme (EORP); ESC Patient Forum; ESC Working Group on Thrombosis and ESC Committee for Young Cardiovascular Professionals; Batra G, Aktaa S, Wallentin L, Maggioni AP, Ludman P, Erlinge D, Casadei B, Gale CP. Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). Eur Heart J. 2022 Jun 21;43(24):2269-2285. doi: 10.1093/eurheartj/ehac133. PubMed 35380662 ↗
  • Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P, Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes. 2022 Jan 5;8(1):4-13. doi: 10.1093/ehjqcco/qcaa069. PubMed 32845314 ↗
  • Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. Eur Heart J. 2019 Sep 1;40(33):2745-2749. doi: 10.1093/eurheartj/ehz599. No abstract available. PubMed 31505603 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 36 months is close to that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 16, 2025
StartActual
Sep 15, 2024
Primary completionEst.
Sep 15, 2027
CompletionEst.
Dec 30, 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07283809
Lead sponsor
Heart Care Foundation
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Sep 15, 2024
Primary completion
Sep 15, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

Furio Colivicchi, MD
Contact
euroheart.italia@heartcarefoundation.itON.IT
055/51013741
Aldo P Maggioni, MD
Contact
maggioni@heartcarefoundation.it
055/5101361

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion